SOLICITATION NOTICE
A -- Antiviral Assessments
- Notice Date
- 6/18/2004
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-40083-NV
- Response Due
- 7/2/2004
- Archive Date
- 7/17/2004
- Point of Contact
- Deborah Moore, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
dm170b@nih.gov, rs442i@nih.gov
- Description
- In accordance with simplified acquisition procedures the National Cancer Institute (NCI), Laboratory of Cell Biology (LCB), Chemical Immunology Section (CIS) plans to procure with ImQuest BioSciences Inc, 7340 Executive Way, Frederick, MD 21704. The CIS has been involved in AIDS research for several years and performs research on the synthesis of novel compounds targeted to retroviral nucleocapsid proteins and determines their suitability as drugs for treating infections with HIV-1 or other retroviruses. ImQuest BioSciences maintains an active Anti-Infective Research Department located in nearby Frederick, MD. The President and Chief Scientific Officer of ImQuest BioSciences is Robert Buckheit, Jr., Ph.D., previously associated with the Department of Infectious Disease at Southern Research Institute (SRI) and TherImmune Research Corporation/Gene Logic Inc (TRC/GLGC). In March 2004, Dr. Buckheit Jr. moved with his HIV experience and capabilities and was joined at ImQuest BioSciences by key professional and technical staff who were associated with the previous years contract from TRC/GLGC. This research team re-established the retrovirus research program at ImQuest BioSciences. The assay offerings of this new program are identical in all technical aspects to the previous year?s contract offering by SRI and TRC/GLGC. However, with the departure of Dr. Buckheit and key personnel, the scientific expertise to develop chemical chemotypes for the discovery of novel NCp7 inhibitors for the treatment and/or prevention of HIV transmission is now only available at ImQuest BioSciences. During the last year, Dr. Buckheit has designed and directed Zn finger inhibitor specific projects that have allowed the selection of lead compounds for in vivo efficacy studies and helped to further define additional classes of NCp7 inhibitors. Assignment of ImQuest BioSciences to this project will allow continuation of the last 2 years of research and ongoing experiments through direct access to the expertise of Dr. Buckheit and his scientific team. To be required to recreate the expertise inherent in ImQuest?s management of this Zn finger project through Dr. Buckheit by another contractor would result in significant delays and expenditures to recreate this service. Thus, the continuation of progress with timeliness and efficiency requires continued usage of Dr. Buckheit and his group. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, without the introduction of new variables into ongoing experiments it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI staff to determine if the party can perform this requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on July 2, 2004. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov . It is the vendor's responsibility to call (301) 402-4509 to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect call will be accepted. NAICS 541380, Size Standard 6M
- Record
- SN00606063-W 20040620/040618211755 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |